Compare Smith & Nephew plc (SNN) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Global X Uranium ETF — how do they compare? Smith & Nephew plc trades at $27.24 (market cap $11.10B), while Global X Uranium ETF trades at $38.9 (market cap $5.48B). The key difference: Smith & Nephew plc is far larger — about 2× Global X Uranium ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while Global X Uranium ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Global X Uranium ETF for 62 Days on average.
| SNN | URA | |
|---|---|---|
Market Cap | $11.10B | $5.48B |
Volume | 1,051,703 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $37.17 | $61.81 |
52-Week Low | $26.42 | $37.52 |
Typical Hold Time | 121 Days | 62 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
URA, the Global X Uranium ETF, trades at $38.56, down 3.43% in the last session amid a bearish technical signal. Key support lies at $37, with resistance at $39. The fund provides exposure to uranium miners and nuclear energy companies, benefiting from structural supply deficits and rising demand for reliable power, particularly from AI data centers. Recent index additions like Terra Innovatum and Eagle Nuclear Energy reflect ongoing sector expansion.
The outlook for URA is mixed; long-term demand drivers from nuclear energy adoption and AI power needs are strong, but near-term price volatility and concentrated holdings pose risks. Investors should weigh the sector's growth potential against ETF-specific fluctuations and broader market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
